证券代码：688089 证券简称：嘉必优 公告编号：2024-044 嘉必优生物技术（武汉）股份有限公司 第一届独立董事专门会议 2024 年第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、独立董事专门会议召开情况 嘉必优生物技术（武汉）股份有限公司（以下简称"公司"）第一届独立 董事专门会议 2024 年第二次会议（以下简称"本次会议"）于 2024 年 11 月 11 日以通讯形式召开。会议通知已于 2024年 11月 8日通过邮件等方式送达全体独 立董事。本次会议应出席独立董事 3 人，实际出席独立董事 3 人。会议由全体 独立董事推举陈向东先生主持。本次会议的召集和召开程序符合《公司法》及 《公司章程》等相关规定。 二、独立董事专门会议审议情况 经过与会独立董事审议表决，形成如下决议： （一）审议通过了《关于公司发行股份及支付现金购买资产并募集配套资 金暨关联交易符合相关法律法规之规定的议案》 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司重 大资产重组管理办法》《上市公司证 ...

证券代码：688089 证券简称：嘉必优 公告编号：2024-040 嘉必优生物技术(武汉)股份有限公司 关于披露发行股份及支付现金购买资产并募集配套资 金暨关联交易预案暨公司股票复牌的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因重大资产重组事项,本公司的相关证券停复牌情况如下： | 证券代 | 证券简称 | 停复牌类型 | | 停牌起始日 | 停牌 | 停牌终止 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | | 码 | | | | | 期间 | 日 | | | 688089 | 嘉必优 | 股 A | 复牌 | | | 2024/11/11 | 2024/11/12 | 一、停牌情况与披露交易预案 嘉必优生物技术(武汉)股份有限公司董事会 嘉必优生物技术（武汉）股份有限公司（以下简称"公司"）拟通过发行股份及 支付现金方式，收购王树伟、董栋、肖云平、王修评、靳超、史贤俊、上海帆易生物 科技合伙企业（有限合伙 ...

证券代码：688089 证券简称：嘉必优 公告编号：2024-039 嘉必优生物技术（武汉）股份有限公司 截至本公告披露之日，公司及有关各方正在积极推进本次交易的相关工作， 公司预计无法在 2024 年 11 月 5 日（星期二）开市起复牌。鉴于本次交易尚存在 不确定性，为维护投资者利益，避免公司股价异常波动，根据《上海证券交易所 科创板股票上市规则》《上市公司股票停复牌规则》相关规定，公司股票（股票 简称：嘉必优，证券代码：688089）自 2024 年 11 月 5 日开市起继续停牌，继续 停牌时间不超过 5 个交易日。停牌期间，公司将根据本次交易相关事项的进展情 况，严格按照有关法律法规的规定和要求及时履行信息披露义务。公司将严格按 照法律法规、规范性文件的有关规定积极推进本次交易筹划事项的各项工作，履 行必要的审议程序，尽快向上海证券交易所提交披露符合相关规定的文件并申请 股票复牌。 公司指定的信息披露媒体为上海证券交易所网站（www.sse.com.cn），有关 本次交易的信息均以在上述指定媒体刊登的为准。公司本次交易事项尚存在不确 定性，敬请广大投资者关注公司后续公告并注意投资风险。 特此公告。 ...

证券代码：688089 证券简称：嘉必优 公告编号：2024-038 嘉必优生物技术（武汉）股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 回购方案首次披露日 | 2024 年 8 月 日 | 28 | | --- | --- | --- | | 回购方案实施期限 | 董事会审议通过后 12 个月内 | | | 预计回购金额 | 1,500 万元-3,000 万元（含） | | | 回购用途 | □减少注册资本 用于员工持股计划或股权激励 □用于转换公司可转债 | | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 万股 0 | | | 累计已回购股数占总股本比例 | 0% | | | 累计已回购金额 | 万元 0 | | | 实际回购价格区间 | 0 元/股~0 元/股 | | 重要内容提示： 一、回购股份的基本情况 2024 年 8 月 27 日，公司召开第三届董事会第二十一次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案 ...

Group 1: Company Overview - The company achieved a revenue of 387 million CNY in the first three quarters of 2024, representing a year-on-year growth of 19.19% [3] - The net profit attributable to shareholders was 83.89 million CNY, with a year-on-year increase of 38.86% [3] - The company focuses on synthetic biology technology, expanding into animal nutrition and personal care sectors [2] Group 2: Market Performance - Domestic market revenue share increased in the third quarter compared to international markets [3] - The company is benefiting from new national standards, the expiration of DSM patents, and the opening of international markets [2] Group 3: Product Development - The new synthetic biology product, 2'-fucosyllactose, has passed health committee review and obtained production licenses, currently in the final stages of production line debugging [3] - The company is actively expanding its product categories and application fields [2] Group 4: Operational Insights - The company's gross margin is influenced by product and customer structure changes, with higher margins in overseas markets [3] - Current production capacity utilization is at a high level, supported by two production bases in Wuhan and a new intelligent manufacturing system [3] - The northern production capacity is in trial production, awaiting customer validation [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The implementation of fertility policies and asset restructuring is expected to strengthen the company's R&D capabilities [3] - The company plans to acquire 65% of Ouyi Biological, which is anticipated to enhance its foundational research strength in synthetic biology [7] - Revenue for Q1-Q3 2024 reached 387 million, a year-on-year increase of 19.2%, while net profit attributable to the parent company increased by 38.9% and 59.7% for the non-deducted and deducted cases respectively [3] Financial Performance Summary - For Q3 2024, revenue was 126 million, a slight increase of 0.2% year-on-year, but net profit attributable to the parent company decreased by 37.4% and 31.2% for the non-deducted and deducted cases respectively [3] - The company has adjusted its net profit forecasts for 2024-2026 to 124 million, 154 million, and 194 million respectively, with corresponding EPS forecasts of 0.74, 0.92, and 1.15 [3] - The current stock price corresponds to PE ratios of 28.4, 22.8, and 18.2 for the years 2024, 2025, and 2026 respectively [3] Market and Business Outlook - Domestic demand for milk powder is expected to improve in the medium to long term due to the implementation of fertility policies [7] - The international market is anticipated to recover in Q4 2024, with order rhythms returning to normal [7] - The company is facing challenges in international business due to shipping factors, but long-term growth is expected post the expiration of patents held by competitors [5][6]

国泰君安版权所有发送给上海东方财富金融数据服务有限公司.东财接收研报邮箱.ybjieshou@eastmoney.com p1 股 票 研 究 证 券 研 究 报 告 股票研究 /[Table_Date] 2024.10.29 ——嘉必优 2024 年三季报点评 [table_Authors]訾猛(分析师) 021-38676442 zimeng@gtjas.com 登记编号S0880513120002 | --- | --- | |----------------------|--------------------| | | | | 闫清徽 ( 分析师 ) | 陈力宇 ( 分析师 ) | | 021-38031651 | 021-38677618 | | yanqinghui@gtjas.com | chenliyu@gtjas.com | | S0880522120004 | S0880522090005 | 收入结构致毛利率承压，拟收购欧易生物 嘉必优(688089) 家庭及个人用品 [Table_Industry] /必需消费 | --- | --- | --- | |--------------- ...

证券代码：688089 证券简称：嘉必优 公告编号：2024-037 嘉必优生物技术（武汉）股份有限公司 一、停牌原因及工作安排 关于筹划重大资产重组的停牌公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券停复牌情况：适用 因筹划重大资产重组事项,本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | | 停牌起始 | | 停牌期 | 停牌终 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 日 | | 间 | 止日 | | | 688089 | 嘉必优 | A 股 | 停牌 | 2024年10 | | | | | | | | | | 月 29 | 日 | | | | 嘉必优生物技术（武汉）股份有限公司（以下简称"公司"、"本公司"）正在 筹划以发行股份及支付现金方式购买上海欧易生物医学科技有限公司（以下简称 "欧易"或"交易标的"）控制权，同时拟募集配套资金（以下简称"本次交 ...

Financial Performance - The company's revenue for Q3 2024 was ¥126,315,510.03, representing a year-over-year increase of 0.20%[2] - The net profit attributable to shareholders for Q3 2024 was ¥16,001,222.04, a decrease of 37.42% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥12,555,040.31, down 31.24% year-over-year[2] - Basic earnings per share for Q3 2024 were ¥0.10, a decrease of 33.33% year-over-year[2] - The net profit attributable to shareholders for the year-to-date period increased by 38.86% compared to the same period last year, driven by higher revenue[6] - Net profit attributable to shareholders of the parent company was CNY 83,890,213.15, compared to CNY 60,414,285.96 in the previous year, marking an increase of 38.7%[17] - The company’s total comprehensive income for the period was CNY 81,174,237.89, compared to CNY 57,112,887.27 in the same period last year, an increase of 42.2%[19] Research and Development - The total R&D investment for Q3 2024 was ¥12,411,114.41, an increase of 19.61% compared to the same period last year, accounting for 9.83% of revenue[3] - Research and development expenses increased to CNY 34,296,787.91, compared to CNY 28,210,281.12, representing a growth of 21.6%[16] - Research and development expenses increased to ¥29,138,534.05 in the first three quarters of 2024, compared to ¥24,260,199.05 in the same period of 2023, reflecting a 20% increase[27] Assets and Liabilities - The company's total assets as of the end of Q3 2024 were ¥1,664,593,510.41, reflecting a 3.30% increase from the end of the previous year[3] - The company's total current assets amount to 672,288,659.48 RMB, a decrease from 708,777,769.17 RMB in the previous period[13] - Non-current assets total 992,304,850.93 RMB, compared to 902,714,862.84 RMB previously, showing an increase of approximately 9.93%[13] - Total liabilities increased to CNY 123,189,945.80 from CNY 117,601,481.29, indicating a rise of 4.5%[15] - The total liabilities of the company amounted to ¥184,245,091.24, an increase from ¥170,821,631.13 in the previous year[26] - The company's total equity reached ¥1,557,366,961.56, up from ¥1,503,874,633.61 in the previous year, indicating a growth of approximately 3.6%[26] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥105,805,187.55, a significant increase of 320.30% compared to the same period last year[6] - Operating cash inflow for the first three quarters of 2024 reached CNY 456.46 million, a 26.67% increase from CNY 360.42 million in the same period of 2023[21] - The net cash flow from operating activities for the first three quarters of 2024 was ¥106,241,108.31, significantly higher than ¥20,021,419.84 in the same period of 2023[30] - Cash flow from financing activities resulted in a net outflow of CNY 28.06 million, an improvement from a net outflow of CNY 42.10 million in the same period last year[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,578[9] - The largest shareholder, Wuhan Xiwang Biological Engineering Co., Ltd., holds 74,340,000 shares, accounting for 44.17% of total shares[9] - The company has not reported any significant changes in shareholder relationships or agreements among the top shareholders[10] Operational Insights - There are no applicable reminders for investors regarding the company's operational situation during the reporting period[11] - The company reported non-recurring gains of ¥3,446,181.72 for Q3 2024, with total non-recurring gains for the year-to-date period amounting to ¥18,328,079.96[5] - The company reported a decrease in other comprehensive income, with a net amount of CNY 12,019.08 compared to a loss of CNY 14,131.82 in the previous year[19] - The company recorded a significant increase in other income, which rose to ¥8,762,039.67 from ¥2,906,263.86 in the previous year[27]